Free shipping on all orders over $ 500

ASP3026

Cat. No. M1950

All AbMole products are for research use only, cannot be used for human consumption.

ASP3026 Structure
Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
1mg USD 27 In stock
5mg USD 54 In stock
10mg USD 80 In stock
50mg USD 180 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

ASP3026 is a potent ALK (Anaplastic Lymphoma Kinase) inhibitor. ASP3026 inhibited ALK kinase activity and was more selective than crizotinib in a Tyr-kinase panel. In an anchorage independent in vitro cell growth assay, ASP3026 inhibited the growth of NCI-H2228, a human NSCLC tumor cell line endogenously expressing EML4-ALK variant 3 and that of 3T3 cells expressing EML4-ALK variant 1, 2 and 3. The plasma and tumor concentrations of ASP3026 in mice xenografted with NCI-H2228 tumor were determined using high-performance liquid chromatography-tandem mass spectrometry. ASP3026 showed potent anti-tumor effects while crizotinib was ineffective even at 100 mg/gk qd in an EML4-ALK driven tumor model with gatekeeper mutation.

Product Citations
Customer Product Validations & Biological Datas
Source Oncotarget (2014). Figure 2. ASP3026
Method apoptosis assay
Cell Lines lymphoma cells
Concentrations 0.5, 1.5, and 2.5 μM
Incubation Time 48 h
Results The occurrence of apoptosis after treatment with ASP3026 was biochemically supported by cleavage of caspase 3 and PARP
Protocol (for reference only)
Cell Experiment
Cell lines NPM-ALK+ ALCL cells Karpas 299, SR-786 and SU-DHL-1 cells
Preparation method MTS assay
Cell viability was measured using MTS reagent (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; Promega, Madison, WI). Briefly, 1 × 105 cells were seeded into 96-well plates, and 20 μL of MTS reagent was added to each well and incubated for approximately 2 h at 37°C in 5% CO2. Plates were read at 490 nm.
Concentrations 0.1, 0.5 and 1 μ M
Incubation time 48 or 72 h
Animal Experiment
Animal models Systemic xenograft NPM-ALK+ ALCL model
Formulation 0.5% methylcellulose
Dosages 30 mg/kg daily for 12 weeks
Administration oral gavage
Chemical Information
Molecular Weight 580.76
Formula C29H40N8O3S
CAS Number 1097917-15-1
Solubility (25°C) DMSO 12 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] George SK, et al. Oncotarget. The ALK inhibitor ASP3026 eradicates NPM-ALK⁺ T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model.

Related ALK Products
AP26113 (Brigatinib)

AP26113 (Brigatinib) is a highly potent ALK inhibitor with IC50 of 0.6 nM.

X-376

X-376 is a potent and highly specific ALK small molecule tyrosine kinase inhibitor with IC50 of 0.61 nM.

SB431542

SB-431542 is a potent and selective inhibitor of the transforming growth factor-β (TGF-β) type I receptor activin receptor-like kinase ALK5 (IC50 = 94 nM).

RepSox

RepSox (ALK5 Inhibitor II) is a potent and ATP-competitive inhibitor of the TGF-β type I receptor ALK5 (IC50 values are 0.004 and 0.023 μM for ALK5 autophosphorylation and ALK5 binding respectively).

LDN-193189

LDN-193189 is a highly potent small molecule inhibitor of bone morphogenetic protein (BMP) type I receptors ALK2 and ALK3.

  Catalog
Abmole Inhibitor Catalog




Keywords: ASP3026 supplier, ALK, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.